Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

92.77 -2.01 (-2.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
Market Monitor May 7 ( Hims & Hers Health, Upwork UP - Palantir, Monderna DOWN)
Markets slide on vaccine regulation fears, trade uncertainty, and cautious earnings despite strong tech and consumer stock moves. 
Via Chartmill
Why BioNTech Stock Got Trounced on Tuesday
Via The Motley Fool
Exposures COVID-19
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion
BioNTech's Q1 revenue hit $192 million, beating estimates; company confirms 2025 outlook and names new CFO ahead of oncology-focused expansion. 
Via Benzinga
Earnings Scheduled For May 5, 2025
Via Benzinga
Want Safe Dividend Income in 2025 and Beyond? Invest in the Following 3 Ultra-High-Yield Stocks.
There's no need to track down complicated and obscure businesses. Some of the market's best income-producing stocks are hiding in plain sight. 
Via The Motley Fool
Topics Bonds World Trade
Exposures COVID-19 Debt Markets Tariff
4 Analysts Have This To Say About BioNTech
Via Benzinga
Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline
The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine has created uncertainty across the vaccine industry, potentially affecting... 
Via Benzinga
Topics Government
Exposures COVID-19 Political Product Safety
Why Is Summit Therapeutics Stock Trading Higher On Monday?
Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 trial. 
Via Benzinga
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today
Via The Motley Fool
Exposures Product Safety
Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps
Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full approval decision. 
Via Benzinga
Exposures COVID-19 Product Safety
BioNTech Surges On Summit's Coattails. But Can They Take On Merck?
BioNTech is on the rise after Summit Therapeutics unveiled promising results for its PD-1- and VEGF-blocking drug. 
Via Investor's Business Daily
Amphenol Posts Better-Than-Expected Results, Joins SAP, Tesla, Pegasystems And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study
Novavax updated Covid vaccine showed fewer and milder side effects than Pfizer-BioNTech's in a Utah study. 
Via Benzinga
Exposures COVID-19
Novavax Retail Traders Rally In Defense After RFK Jr.'s COVID-19 Vaccine Skepticism Sends Stock Tumbling
Kennedy singled out the Novavax COVID-19 shot's single-antigen composition as the reason behind the delay in granting full approval. 
Via Stocktwits
Exposures COVID-19 Product Safety
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.
From vaccines to fluoride and beef tallow, here's where Robert F. Kennedy Jr. is making changes to health care. 
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety
BioNTech Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Via Benzinga
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in July 2025. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
BioNTech's 2025 Revenue View, Vaccine Policy Uncertainty Prompt Price-Target Cut: Retail Stays Cautiously Optimistic
For the current year, BioNTech projected revenue of 1.7 billion euros to 2.2 billion euros, below the market consensus of 2.54 billion euros and a fall from last year's 2.75 billion euros. 
Via Stocktwits
BioNTech Se (BNTX) Q4 2024 Earnings Call Transcript
BNTX earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday?
Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQ:TSLA) and Palantir... 
Via Benzinga
Topics Economy Stocks
Exposures Economy US Equities
Pfizer's COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations
BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key data updates expected in 2025. 
Via Benzinga
Exposures COVID-19
BioNTech Surpasses Q4 Revenue Estimates
BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue. 
Via The Motley Fool
US Stocks Likely To Open Lower After Trump Hints At Looming Recession: Expert Says Can't Rule Out A Bear Market As Indices Inch Towards Correction Territory
U.S. stock futures declined on Monday after a small bout of relief on Friday as indices neared the correction zone. 
Via Benzinga
Topics Government
Exposures Political
Earnings Scheduled For March 10, 2025
Via Benzinga
Dow Gains Over 200 Points But Records Weekly Loss: Fear Among Investors Eases But Greed Index Remains In 'Extreme Fear' Zone
Via Benzinga
Topics Stocks
Exposures US Equities
BioNTech, Oracle And 3 Stocks To Watch Heading Into Monday
Via Benzinga
Nasdaq Falls Into Correction As Tariffs Roil Wall Street: What's Moving Markets Friday?
All three major indices were red in Friday’s midday trading, with the S&P 500 and Nasdaq 100 down 1% and 1.24%, respectively, and on track for their worst weeks since September 2024. 
Via Benzinga
Why Moderna Stock Has Surged 20% This Week Despite Mixed News
Recent news has been mixed with a patent win and loss in Germany and the U.S. But Moderna stock has risen markedly this week. 
Via Investor's Business Daily
Topics Intellectual Property
Exposures Intellectual Property
BioNTech Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.